These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7721546)

  • 1. Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1994 Dec; 29(12):1050-6. PubMed ID: 7721546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detectability of small liver metastases with gadolinium BOPTA.
    Runge VM; Lee C; Williams NM
    Invest Radiol; 1997 Sep; 32(9):557-65. PubMed ID: 9291044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-enhanced magnetic resonance imaging in a spinal epidural tumor model.
    Runge VM; Lee C; Iten AL; Williams NM
    Invest Radiol; 1997 Oct; 32(10):589-95. PubMed ID: 9342117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic abscesses. Magnetic resonance imaging findings using gadolinium-BOPTA.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Dec; 31(12):781-8. PubMed ID: 8970881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.
    Yuh WT; Fisher DJ; Runge VM; Atlas SW; Harms SE; Maravilla KR; Mayr NA; Mollman JE; Price AC
    AJNR Am J Neuroradiol; 1994 Jun; 15(6):1037-51. PubMed ID: 8073972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal metastasis. Detection and characterization on enhanced magnetic resonance imaging using an animal model.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1997 Apr; 32(4):212-7. PubMed ID: 9101356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose gadoteridol in MR imaging of intracranial neoplasms.
    Runge VM; Kirsch JE; Burke VJ; Price AC; Nelson KL; Thomas GS; Dean BL; Lee C
    J Magn Reson Imaging; 1992; 2(1):9-18. PubMed ID: 1623287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of standard and high-dose contrast-enhanced breath-hold liver magnetic resonance for visualization of metastatic disease in an animal model.
    Runge VM
    Invest Radiol; 1998 May; 33(5):263-7. PubMed ID: 9609484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.
    Brekenfeld C; Foert E; Hundt W; Kenn W; Lodeann KP; Gehl HB
    Invest Radiol; 2001 May; 36(5):266-75. PubMed ID: 11323514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of gadolinium 2,5-BPA-DO3A, a new macrocyclic hepatobiliary chelate, in normal liver and metastatic disease on high field magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Jan; 31(1):11-6. PubMed ID: 8850360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gadolinium Cy2DOTA, a new hepatobiliary agent, and gadolinium HP-DO3A, an extracellular agent, in healthy liver and metastatic disease.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1995 Feb; 30(2):123-30. PubMed ID: 7782188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early dynamic magnetic resonance imaging of liver metastases with 0.3 and 0.6 mmol/kg gadoteridol injection.
    Runge VM; Wells JW; Williams NM
    Invest Radiol; 1996 Aug; 31(8):472-8. PubMed ID: 8854193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
    Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
    Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detectability of early brain meningitis with magnetic resonance imaging.
    Runge VM; Wells JW; Williams NM; Lee C; Timoney JF; Young AB
    Invest Radiol; 1995 Aug; 30(8):484-95. PubMed ID: 8557515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.
    Kuhn MJ; Hammer GM; Swenson LC; Youssef HT; Gleason TJ
    Comput Med Imaging Graph; 1994; 18(5):391-9. PubMed ID: 7954317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose applications of gadolinium chelates in magnetic resonance imaging.
    Runge VM; Kirsch JE; Thomas GS
    Magn Reson Med; 1991 Dec; 22(2):358-63. PubMed ID: 1812371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of cerebral perfusion by first-pass, dynamic, contrast-enhanced, steady-state free-precession MR imaging: an animal study.
    Runge VM; Kirsch JE; Wells JW; Woolfolk CE
    AJR Am J Roentgenol; 1993 Mar; 160(3):593-600. PubMed ID: 8430562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent.
    Carvlin MJ; De Simone DN; Meeks MJ
    Invest Radiol; 1992 Aug; 27 Suppl 1():S16-21. PubMed ID: 1506148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic contrast-enhanced magnetic resonance imaging in a model of splenic metastasis.
    Runge VM; Williams NM
    Invest Radiol; 1998 Jan; 33(1):45-50. PubMed ID: 9438509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.
    Runge VM; Wells JW; Nelson KL; Linville PM
    J Magn Reson Imaging; 1994; 4(5):669-73. PubMed ID: 7981511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.